BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target
BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.
Stocks · News reference
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Carelon Health Services To Cover Guardant Health’s Shield Blood Test
Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield lives ages 45 and